Editor's Note: Research & Development Findings Only
Please be advised that the below press release was issued for product produced in New Zealand for the parent company of Zoono USA, and it reports data that is valid, but inadmissible to the US EPA for a Surface-Treatment-Classified product.
Furthermore, this was a test of one of the inert ingredients - NOT the active ingredient that provides Zoono Microbe-Shield and Germ-Free 24 with its long-lasting characteristics, and allows for even better performance.
Zoono Group Limited (ASX: ZNO) is pleased to advise that it has today received the report for the laboratory tests undertaken against COVID-19. The results show that Zoono's Z-71 Microbe Shield (the same Zoono technology used in Zoono hand sanitiser) is > 99.99% effective against COVOID-19.
COVID-19 has become a global concern, in particular as it has been shown to survive on surfaces for up to 9 days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.
Whilst Zoono had been previously tested against bovine coronavirus (the nominated surrogate for MERS), this latest strain required new testing.
Two separate tests were completed to EN Standard 14476:2013+A2:2019. The first was against Vaccinia; sometimes referred to as the 'mother ship' of double enveloped viruses (that are particularly hard to inactivate), with the subsequent test against the nominated (and globally accepted) surrogate for COVID19; feline coronavirus.
EN14476 is the European Standard that applies to products within the medical area including hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means.
RESULTS:
The test against Vaccinia confirmed efficacy of > 4Log (greater than 99.99% efficacy) for Zoono Z-71 Microbe Shield (the same Zoono technology used in Zoono Hand Sanitiser).
The second test against the COVID-19 surrogate, feline coronavirus, confirmed efficacy at 4.33Log (greater than 99.99% efficacy).
The members of the family Coronaviridae are enveloped and have positive sense RNA genome. Coronaviruses have a distinct morphology with an outer 'corona' of embedded envelope spikes. These viruses cause a broad spectrum of animal and human disease and are particularly difficult to inactivate.
Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID-19 Virus.
Please Note: Tests were conducted in Germany in accordance with: European Standard EN14476:2013+A2:2019.
